A Phase III Randomised, Partially Double-blind and Placebo-controlled Study of BI 207127 in Combination With Faldaprevir and Ribavirin for Chronic Genotype 1 Hepatitis C Infection in an Extended Population of Treatment naive Patients That Includes Those Ineligible to Receive Peginterferon
Phase of Trial: Phase III
Latest Information Update: 30 Jun 2017
At a glance
- Drugs Deleobuvir (Primary) ; Faldaprevir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Registrational; Therapeutic Use
- Acronyms HCVerso-2
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 04 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 26 Jan 2015 Planned End Date changed from 1 Dec 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 30 Apr 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Sep 2015 to 1 Dec 2014.